Skip to main
DNTH

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc. is positioned for significant growth, with anticipated share price increases of 25%-30% under a logical base case scenario and a projected 15% increase based on an interim assessment upgrade. The pipeline highlights the potential of Claseprubart, which is expected to demonstrate greater potency and efficacy compared to riliprubart, further enhancing investor optimism surrounding the transition to Phase B of the CAPTIVATE trial. Additionally, a projected year-end cash balance of approximately $514 million underpins the company’s robust financial health, contributing to a revised target valuation of $55, up from $46, reflecting the overall favorable outlook for the stock.

Bears say

Dianthus Therapeutics Inc. faces significant financial challenges, particularly the risk of insufficient funding, which may hinder its ability to advance its therapeutic pipeline, including Claseprubart. The company's reliance on external capital raises concerns about its financial stability and the timing of its product development, especially if interim results are unsuccessful. These fundamental financial weaknesses contribute to a negative outlook on the company's stock performance.

DNTH has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 11 analysts, DNTH has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $123.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $123.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.